rs3751663
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -15 ACMG points: 0P and 15B. BP4_StrongBP6_ModerateBP7BS1BS2
The NM_021098.3(CACNA1H):c.2031G>A(p.Ser677Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000312 in 1,572,514 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000032 ( 0 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -4.73
Publications
2 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -15 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 16-1204038-G-A is Benign according to our data. Variant chr16-1204038-G-A is described in ClinVar as [Benign]. Clinvar id is 529596.Status of the report is criteria_provided_single_submitter, 1 stars.
BP7
Synonymous conserved (PhyloP=-4.73 with no splicing effect.
BS1
Variant frequency is greater than expected in population eas. GnomAdExome4 allele frequency = 0.0000324 (46/1420222) while in subpopulation EAS AF = 0.000777 (29/37336). AF 95% confidence interval is 0.000555. There are 0 homozygotes in GnomAdExome4. There are 23 alleles in the male GnomAdExome4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAdExome4 at 46 AD gene.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1H | ENST00000348261.11 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
CACNA1H | ENST00000569107.6 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 34 | 1 | ENSP00000454990.2 | |||
CACNA1H | ENST00000711493.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 34 | ENSP00000518778.1 | ||||
CACNA1H | ENST00000565831.7 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 34 | 1 | ENSP00000455840.1 | |||
CACNA1H | ENST00000711450.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 35 | ENSP00000518762.1 | ||||
CACNA1H | ENST00000564231.6 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 35 | 1 | ENSP00000457555.2 | |||
CACNA1H | ENST00000638323.1 | c.1992G>A | p.Ser664Ser | synonymous_variant | Exon 10 of 35 | 5 | ENSP00000492267.1 | |||
CACNA1H | ENST00000562079.6 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 34 | 1 | ENSP00000454581.2 | |||
CACNA1H | ENST00000711438.1 | c.1992G>A | p.Ser664Ser | synonymous_variant | Exon 10 of 34 | ENSP00000518754.1 | ||||
CACNA1H | ENST00000711482.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 36 | ENSP00000518771.1 | ||||
CACNA1H | ENST00000711485.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 35 | ENSP00000518774.1 | ||||
CACNA1H | ENST00000711455.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 36 | ENSP00000518768.1 | ||||
CACNA1H | ENST00000711483.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 35 | ENSP00000518772.1 | ||||
CACNA1H | ENST00000711456.1 | c.2031G>A | p.Ser677Ser | synonymous_variant | Exon 10 of 34 | ENSP00000518769.1 | ||||
CACNA1H | ENST00000621827.2 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 37 | 6 | ENSP00000518766.1 | ||||
CACNA1H | ENST00000637236.3 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 34 | 5 | ENSP00000492650.2 | ||||
CACNA1H | ENST00000639478.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 35 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000640028.1 | n.1414G>A | non_coding_transcript_exon_variant | Exon 10 of 35 | 5 | ENSP00000491488.1 | ||||
CACNA1H | ENST00000711442.1 | n.*1478G>A | non_coding_transcript_exon_variant | Exon 9 of 34 | ENSP00000518758.1 | |||||
CACNA1H | ENST00000711448.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 36 | ENSP00000518760.1 | |||||
CACNA1H | ENST00000711449.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 35 | ENSP00000518761.1 | |||||
CACNA1H | ENST00000711451.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 36 | ENSP00000518763.1 | |||||
CACNA1H | ENST00000711452.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 36 | ENSP00000518764.1 | |||||
CACNA1H | ENST00000711453.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 36 | ENSP00000518765.1 | |||||
CACNA1H | ENST00000711484.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 35 | ENSP00000518773.1 | |||||
CACNA1H | ENST00000711486.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 37 | ENSP00000518775.1 | |||||
CACNA1H | ENST00000711487.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 36 | ENSP00000518776.1 | |||||
CACNA1H | ENST00000711488.1 | n.2031G>A | non_coding_transcript_exon_variant | Exon 10 of 35 | ENSP00000518777.1 | |||||
CACNA1H | ENST00000711442.1 | n.*1478G>A | 3_prime_UTR_variant | Exon 9 of 34 | ENSP00000518758.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152172Hom.: 0 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
3
AN:
152172
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.0000109 AC: 2AN: 183994 AF XY: 0.0000199 show subpopulations
GnomAD2 exomes
AF:
AC:
2
AN:
183994
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000324 AC: 46AN: 1420222Hom.: 0 Cov.: 32 AF XY: 0.0000327 AC XY: 23AN XY: 702834 show subpopulations
GnomAD4 exome
AF:
AC:
46
AN:
1420222
Hom.:
Cov.:
32
AF XY:
AC XY:
23
AN XY:
702834
show subpopulations
African (AFR)
AF:
AC:
1
AN:
32472
American (AMR)
AF:
AC:
0
AN:
39838
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
25408
East Asian (EAS)
AF:
AC:
29
AN:
37336
South Asian (SAS)
AF:
AC:
1
AN:
81434
European-Finnish (FIN)
AF:
AC:
0
AN:
47314
Middle Eastern (MID)
AF:
AC:
0
AN:
5704
European-Non Finnish (NFE)
AF:
AC:
14
AN:
1091878
Other (OTH)
AF:
AC:
1
AN:
58838
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.479
Heterozygous variant carriers
0
3
7
10
14
17
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152292Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74458 show subpopulations
GnomAD4 genome
AF:
AC:
3
AN:
152292
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74458
show subpopulations
African (AFR)
AF:
AC:
0
AN:
41566
American (AMR)
AF:
AC:
2
AN:
15312
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3470
East Asian (EAS)
AF:
AC:
1
AN:
5168
South Asian (SAS)
AF:
AC:
0
AN:
4820
European-Finnish (FIN)
AF:
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
0
AN:
68008
Other (OTH)
AF:
AC:
0
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
3
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jul 30, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.